Silvia Marchesi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Silvia Marchesi has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Mario Occhipinti
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy
2 shared publications A. Guidolin
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Oncology Unit, Careggi University Hospital, Florence, Italy
1 shared publicationA. Pretta
Medical Oncology, University Hospital, Cagliari, Italy
1 shared publication- Alessia Vendittelli
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy
1 shared publication - Andra Diana Dumitrascu
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan 20133, Italy
1 shared publication Andrea Bottelli
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
1 shared publication
Latest Publications
- Open Access
Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study
Introduction: First-line treatment options for EGFR-mutated NSCLC have expanded beyond osimertinib monotherapy following the FLAURA2 and MARIPOSA trials, which demonstrated improved long-term outcomes with combination strategies, albeit with increased toxicities. Given that randomized controlled trials (RCTs) typically enroll highly selected patients (pts), evaluating the representativeness of these cohorts in real-world (RW) practice is essential to inform RCT applicability. Methods: We retrospectively identified patients with EGFR-mutated advanced NSCLC treated with first-line osimertinib at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, between January 2019 and August 2025. Clinical characteristics were collected, and eligibility for FLAURA, FLAURA2, and MARIPOSA was assessed according to the respective trial criteria. For survival analyses, patients were classified as trial-eligible or trial-ineligible according to FLAURA eligibility criteria, as all patients received first-line osimertinib. Results: Overall, 135 pts were included in the analysis; median age was 67 years (IQR 57–76), 17% had ECOG PS 2, and 11% harbored uncommon EGFR mutations. Only 31 patients (23%) met eligibility criteria for all three trials, whereas 91 (67%) were ineligible for all. The most frequent exclusion criteria included symptomatic CNS disease or spinal cord compression, ECOG PS 2, and EGFR mutation assessment by cytology or liquid biopsy. Both real-world progression free survival (rwPFS) and overall survival (OS) were numerically longer in trial-eligible than trial-ineligible patients (20.1 vs. 18.2 months and 29.9 vs. 22.3 months, respectively). Patients with negative prognostic characteristics such as ECOG PS ≥ 2, uncommon EGFR mutations, and liver metastases had significantly shorter OS, while other predefined risk factors showed only numerical trends. Conclusions: A substantial proportion of patients treated with first-line osimertinib in routine practice would not have met the eligibility criteria of pivotal EGFR-mutated NSCLC trials. Trial-ineligible patients had numerically shorter survival, likely reflecting adverse baseline characteristics. These findings highlight the limitations of direct extrapolation of RCT results to real-world populations.
Open AccessReal-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study
Introduction: First-line treatment options for EGFR-mutated NSCLC have expanded beyond osimertinib monotherapy following the FLAURA2 and MARIPOSA trials, which demonstrated improved long-term outcomes with combination strategies, albeit with increased toxicities. Given that randomized controlled trials (RCTs) typically enroll highly selected patients (pts), evaluating the representativeness of these cohorts in real-world (RW) practice is essential to inform RCT applicability. Methods: We retrospectively identified patients with EGFR-mutated advanced NSCLC treated with first-line osimertinib at Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, between January 2019 and August 2025. Clinical characteristics were collected, and eligibility for FLAURA, FLAURA2, and MARIPOSA was assessed according to the respective trial criteria. For survival analyses, patients were classified as trial-eligible or trial-ineligible according to FLAURA eligibility criteria, as all patients received first-line osimertinib. Results: Overall, 135 pts were included in the analysis; median age was 67 years (IQR 57–76), 17% had ECOG PS 2, and 11% harbored uncommon EGFR mutations. Only 31 patients (23%) met eligibility criteria for all three trials, whereas 91 (67%) were ineligible for all. The most frequent exclusion criteria included symptomatic CNS disease or spinal cord compression, ECOG PS 2, and EGFR mutation assessment by cytology or liquid biopsy. Both real-world progression free survival (rwPFS) and overall survival (OS) were numerically longer in trial-eligible than trial-ineligible patients (20.1 vs. 18.2 months and 29.9 vs. 22.3 months, respectively). Patients with negative prognostic characteristics such as ECOG PS ≥ 2, uncommon EGFR mutations, and liver metastases had significantly shorter OS, while other predefined risk factors showed only numerical trends. Conclusions: A substantial proportion of patients treated with first-line osimertinib in routine practice would not have met the eligibility criteria of pivotal EGFR-mutated NSCLC trials. Trial-ineligible patients had numerically shorter survival, likely reflecting adverse baseline characteristics. These findings highlight the limitations of direct extrapolation of RCT results to real-world populations.
- Open Access
- 26 December 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma
The treatment landscape for patients with advanced gastric or gastroesophageal junction adenocarcinoma is evolving, driven by a deeper understanding of molecular profiling and the introduction of novel anticancer drugs. Systemic chemotherapy has improved survival compared to supportive care; however, overall survival worldwide remained limited to approximately 1 year. Recently, the introduction of upfront immune checkpoint inhibitors (ICIs) and/or targeted agents in biomarker-enriched populations has led to clinically meaningful survival improvements. The expansion of treatment options for metastatic disease, combined with the identification of biomarker-selected populations, underscores the importance of tailoring first-line, maintenance, and sequential therapies across multiple lines. In this context, the delivery of an effective first-line treatment is crucial, as less than half of patients retain fitness for additional anti-cancer therapies due to the morbidity associated with disease progression to the initial regimen even within modern clinical trials regardless of the use of targeted therapy or immunotherapy combined with chemotherapy. On the other hand, the expanding therapeutic armamentarium including ICIs, antibody-drug conjugates, and targeted therapies for molecularly selected subgroups, will enable the development of sequential treatment strategies across multiple lines of therapy. This review summarizes the current knowledge about maintenance strategies and subsequent lines of treatment in either biomarker selected and unselected populations.
- 26 December 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessFirst-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma
The treatment landscape for patients with advanced gastric or gastroesophageal junction adenocarcinoma is evolving, driven by a deeper understanding of molecular profiling and the introduction of novel anticancer drugs. Systemic chemotherapy has improved survival compared to supportive care; however, overall survival worldwide remained limited to approximately 1 year. Recently, the introduction of upfront immune checkpoint inhibitors (ICIs) and/or targeted agents in biomarker-enriched populations has led to clinically meaningful survival improvements. The expansion of treatment options for metastatic disease, combined with the identification of biomarker-selected populations, underscores the importance of tailoring first-line, maintenance, and sequential therapies across multiple lines. In this context, the delivery of an effective first-line treatment is crucial, as less than half of patients retain fitness for additional anti-cancer therapies due to the morbidity associated with disease progression to the initial regimen even within modern clinical trials regardless of the use of targeted therapy or immunotherapy combined with chemotherapy. On the other hand, the expanding therapeutic armamentarium including ICIs, antibody-drug conjugates, and targeted therapies for molecularly selected subgroups, will enable the development of sequential treatment strategies across multiple lines of therapy. This review summarizes the current knowledge about maintenance strategies and subsequent lines of treatment in either biomarker selected and unselected populations.
- Open Access
- 2 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-13
Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment
Immune-checkpoint targeting Drug Conjugates (IDCs) are a novel class of therapeutics that combine an immune checkpoint-targeting moiety, a cleavable linker, and a cytotoxic payload. By integrating features and functions of antibody-drug conjugates and immunotherapy, IDCs represent a promising strategy to remodel the tumor microenvironment and enhance antitumor efficacy. Several IDCs targeting checkpoints such as PD-L1, B7-H3, and B7-H4 are in early-phase clinical trials. This review summarizes available data on IDC efficacy and toxicity in human. Although current evidence is limited, ongoing phase III trials and biomarker studies will clarify their optimal clinical role, including potential for tumor-agnostic use.
- 2 July 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 9 (1) , 1-13
Open AccessImmune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment
Immune-checkpoint targeting Drug Conjugates (IDCs) are a novel class of therapeutics that combine an immune checkpoint-targeting moiety, a cleavable linker, and a cytotoxic payload. By integrating features and functions of antibody-drug conjugates and immunotherapy, IDCs represent a promising strategy to remodel the tumor microenvironment and enhance antitumor efficacy. Several IDCs targeting checkpoints such as PD-L1, B7-H3, and B7-H4 are in early-phase clinical trials. This review summarizes available data on IDC efficacy and toxicity in human. Although current evidence is limited, ongoing phase III trials and biomarker studies will clarify their optimal clinical role, including potential for tumor-agnostic use.
- 8 November 2024
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 29 (1) , 55-66
Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives
Mesothelioma is a malignant tumor associated primarily with asbestos exposure, characterized by an aggressive nature and poor prognosis. Accurate diagnosis, staging, and monitoring of therapeutic response are crucial for effective patient management. Along with a computed tomography (CT) scan, fluorodeoxyglucose labeled with fluorine-18 ([18F]FDG) positron emission tomography (PET) is commonly used in mesothelioma evaluation. However, it has some limitations, including lower sensitivity after pleurodesis and poor accuracy for involved lymph node evaluation. Thus, there is the need to explore other agents. The aim of the present review is to analyze the current literature on the use of alternative radiopharmaceuticals for PET imaging in patients with mesothelioma. A comprehensive search of scientific databases (PubMed, Scopus, and Web of Science) for studies published in the last decade was performed by using the following keywords: “mesothelioma” AND “PET” AND “PET/CT” “radiopharmaceuticals”, “[18F]FDG alternatives”. Articles focused solely on [18F]FDG, non-English publications or preclinical studies, reviews, meeting abstracts, letters to the editors, and editorials were excluded. A qualitative assessment was made by using the Critical Appraisal Skills Programme (CASP) checklist for diagnostic test studies, when applicable. In total, 14 papers were selected; in seven articles more than five patients were enrolled, while the other seven were only clinical cases (enrolling up to two subjects). [18F]/gallium-68 ([68Ga])-labeled fibroblast activation protein inhibitor (FAPI) compounds, [18F]Fluorothymidine ([18F]FLT), methionine labeled with carbon-11 ([11C]MET), and fluoromisonidazole labeled with fluorine-18 ([18F]FMISO) PET/CT were the alternative agents used most often. In 12 articles, [18F]FDG PET/CT was used as a comparator imaging modality. Detection rate of [18F]FDG was similar to the other radiopharmaceuticals ([68Ga]/[18F]-labeled FAPI compounds, [18F]FLT, [18F]FMISO, [11C]MET, and [68Ga]-Pentaxifor), although radiolabeled FAPI seems to exhibit a higher diagnostic performance. [18F]FDG is still a valuable agent in patients with mesothelioma. However, radiolabeled FAPI appears to be promising and its theranostic properties should therefore be further assessed.
- 8 November 2024
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 29 (1) , 55-66
Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [18F]FDG Alternatives
Mesothelioma is a malignant tumor associated primarily with asbestos exposure, characterized by an aggressive nature and poor prognosis. Accurate diagnosis, staging, and monitoring of therapeutic response are crucial for effective patient management. Along with a computed tomography (CT) scan, fluorodeoxyglucose labeled with fluorine-18 ([18F]FDG) positron emission tomography (PET) is commonly used in mesothelioma evaluation. However, it has some limitations, including lower sensitivity after pleurodesis and poor accuracy for involved lymph node evaluation. Thus, there is the need to explore other agents. The aim of the present review is to analyze the current literature on the use of alternative radiopharmaceuticals for PET imaging in patients with mesothelioma. A comprehensive search of scientific databases (PubMed, Scopus, and Web of Science) for studies published in the last decade was performed by using the following keywords: “mesothelioma” AND “PET” AND “PET/CT” “radiopharmaceuticals”, “[18F]FDG alternatives”. Articles focused solely on [18F]FDG, non-English publications or preclinical studies, reviews, meeting abstracts, letters to the editors, and editorials were excluded. A qualitative assessment was made by using the Critical Appraisal Skills Programme (CASP) checklist for diagnostic test studies, when applicable. In total, 14 papers were selected; in seven articles more than five patients were enrolled, while the other seven were only clinical cases (enrolling up to two subjects). [18F]/gallium-68 ([68Ga])-labeled fibroblast activation protein inhibitor (FAPI) compounds, [18F]Fluorothymidine ([18F]FLT), methionine labeled with carbon-11 ([11C]MET), and fluoromisonidazole labeled with fluorine-18 ([18F]FMISO) PET/CT were the alternative agents used most often. In 12 articles, [18F]FDG PET/CT was used as a comparator imaging modality. Detection rate of [18F]FDG was similar to the other radiopharmaceuticals ([68Ga]/[18F]-labeled FAPI compounds, [18F]FLT, [18F]FMISO, [11C]MET, and [68Ga]-Pentaxifor), although radiolabeled FAPI seems to exhibit a higher diagnostic performance. [18F]FDG is still a valuable agent in patients with mesothelioma. However, radiolabeled FAPI appears to be promising and its theranostic properties should therefore be further assessed.
- Open Access
- 27 March 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (4) , 3684-3696
Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
Lung cancer is the leading cause of cancer deaths in the world. Surgery is the most potentially curative therapeutic option for patients with early-stage non-small cell lung cancer (NSCLC). The five-year survival for these patients remains poor and variable, depending on the stage of disease at diagnosis, and the risk of recurrence following tumor resection is high. During the last 20 years, there has been a modest improvement in the therapeutic strategies for resectable NSCLC. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, have become the cornerstone for the treatment of metastatic NSCLC patients. Recently, their clinical development has been shifted in the neoadjuvant and adjuvant settings where they have demonstrated remarkable efficacy, leading to improved clinical outcomes. Based on the positive results from phase III trials, ICIs have become a therapeutic option in neoadjuvant and adjuvant settings. On October 2021 the Food and Drug Administration (FDA) approved atezolizumab as an adjuvant treatment following surgery and platinum-based chemotherapy for patients with NSCLC whose tumors express PD-L1 ≥ 1%. In March 2022, nivolumab in combination with platinum-doublet chemotherapy was approved for adult patients with resectable NSCLC in the neoadjuvant setting. The current review provides an updated overview of the clinical trials exploring the role of immunotherapy in patients with early-stage NSCLC, focusing on the biological rationale for their use in the perioperative setting. We will also discuss the role of potential predictive biomarkers to personalize therapy and optimize the incorporation of immunotherapy into the multimodality management of stage I-III NSCLC.
- 27 March 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (4) , 3684-3696
Open AccessImmunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives
Lung cancer is the leading cause of cancer deaths in the world. Surgery is the most potentially curative therapeutic option for patients with early-stage non-small cell lung cancer (NSCLC). The five-year survival for these patients remains poor and variable, depending on the stage of disease at diagnosis, and the risk of recurrence following tumor resection is high. During the last 20 years, there has been a modest improvement in the therapeutic strategies for resectable NSCLC. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, have become the cornerstone for the treatment of metastatic NSCLC patients. Recently, their clinical development has been shifted in the neoadjuvant and adjuvant settings where they have demonstrated remarkable efficacy, leading to improved clinical outcomes. Based on the positive results from phase III trials, ICIs have become a therapeutic option in neoadjuvant and adjuvant settings. On October 2021 the Food and Drug Administration (FDA) approved atezolizumab as an adjuvant treatment following surgery and platinum-based chemotherapy for patients with NSCLC whose tumors express PD-L1 ≥ 1%. In March 2022, nivolumab in combination with platinum-doublet chemotherapy was approved for adult patients with resectable NSCLC in the neoadjuvant setting. The current review provides an updated overview of the clinical trials exploring the role of immunotherapy in patients with early-stage NSCLC, focusing on the biological rationale for their use in the perioperative setting. We will also discuss the role of potential predictive biomarkers to personalize therapy and optimize the incorporation of immunotherapy into the multimodality management of stage I-III NSCLC.
- Open Access
- 29 September 2022
- Published by Elsevier in Resuscitation Plus
- Vol. 12, 100311
Suction cup on a piston-based chest compression device improves coronary perfusion pressure and cerebral oxygenation during experimental cardiopulmonary resuscitation
- 29 September 2022
- Published by Elsevier in Resuscitation Plus
- Vol. 12, 100311
Open AccessSuction cup on a piston-based chest compression device improves coronary perfusion pressure and cerebral oxygenation during experimental cardiopulmonary resuscitation